&Partners’s LifeVantage LFVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$207K Sell
33,125
-5,696
-15% -$34.5K ﹤0.01% 2361
2026
Q1
$168K Buy
38,821
+20,259
+109% +$106K ﹤0.01% 2281
2025
Q4
$114K Sell
18,562
-969
-5% -$7.17K ﹤0.01% 2202
2025
Q3
$190K Buy
19,531
+1,684
+9% +$21.1K ﹤0.01% 1973
2025
Q2
$220K Buy
17,847
+481
+3% +$6.22K ﹤0.01% 1787
2025
Q1
$250K Buy
17,366
+6,773
+64% +$128K ﹤0.01% 1501
2024
Q4
$188K Buy
+10,593
New +$149K ﹤0.01% 1546

Other funds holding LFVN

&Partners's LFVN Position: Q2 2026 in Review

&Partners reduced its LifeVantage (LFVN) stake by 15% in Q2 2026, selling an estimated $34.5K and leaving 33,125 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #2361.

&Partners first reported a position in LFVN in Q4 2024 and has held it in 7 quarters since. The position peaked at $250K in Q1 2025. 89 funds tracked by Wall St. Rank hold LFVN as of Q2 2026.

  • &Partners held 33,125 shares of LifeVantage worth $207K as of Q2 2026.
  • &Partners sold 5,696 LifeVantage shares in Q2 2026, an estimated $34.5K.
  • LifeVantage made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2361 holding.
  • &Partners first reported a position in LifeVantage in Q4 2024 and has held it in 7 quarters since.
  • &Partners's LifeVantage position peaked at $250K in Q1 2025.
  • 89 funds tracked by Wall St. Rank held LifeVantage as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.